Phase 1 N=39 Pharmacokinetics and Hepatic Safety of EGCG
Uterine Fibroids
Primary: Changes in Epigallocatechin Gallate (EGCG) — 5.8; 256.3; 86.4 nM — p=0.112
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=22 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
Primary Immunodeficiency
Primary: AUC (0-7): Area Under the Concentration Time Curve Over a Dosing Interval of Either Every 3 Weeks [AUC0-21 Days] or Every 4 Weeks [AUC0-28 Days] for Total Immunoglobulin…
Phase 3 N=509 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Psoriasis
Primary: The Mean Percent Improvement From Baseline in PASI Score at Week 12 — 77.93; 75.89 percentage of improvement in PASI score
N/A N=108 A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI
ART
Primary: Percentage of Good Quality Blastocyst Formation — 51.4; 51.7 percentage of embryos
Phase 2 N=39 A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6 — -1.4; -2.5 Units on a scale
Phase 4 N=129 Toward Zero Prescribed Opioids for Outpatient General Surgery
Opioid Misuse and Addiction · Pain
Primary: Morphine Milligram Equivalents Taken by Participants — 46; 15; 0 morphine milligram equivalents
Phase 3 N=399 Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
Severe COVID-19 Pneumonia
Primary: Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS) — 15.5; 31.9 percentage of change — p=0.3677
Phase 1 N=33 A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
HIV Infections
Primary: Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC [0-inf]) of DTG, ABC and 3TC Following Administration of…
N/A N=99 COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
Sars-CoV-2 Infection · COVID-19
Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants
N/A N=310 Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Percentage of Readings Within 20% Agreement — 88.9; 87.5; 87.9 percentage of readings — p=<0.05
N/A N=63 Care to Plan: a Tailored Resource for Family Members of Persons With Dementia
Dementia · Alzheimer Disease · Memory Loss
Primary: Caregiver Self-efficacy — 3.62; 3.36; 3.84; 3.57 scores on a scale
N/A N=40 Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
HIV
Primary: Myocardial Perfusion by PET — 0.01; -0.07 unitless — p=0.72
N/A N=31 Wearable Robotic System and Robotic Mirror Therapy in Spastic Hemiplegia Post Botulinum Toxin Injection
Hemiplegia, Spastic · Spastic
Primary: Fugl-Meyer Assessment (FMA) — 3; 6 score on a scale
Phase 2 N=57 A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
Infantile Spasms
Primary: Change From Baseline in Frequency of Spasm Clusters at Day 10 — 1.0; 2.7; -5.4; -1.0 Spasm clusters per day — p=0.7391
Phase 4 N=27 Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder
Posttraumatic Stress Disorder
Primary: The Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Score at Week 2 — 16.6; 17.1 score on a scale